Drug Search Results
More Filters [+]

Cudetaxestat

Alternative Names: Cudetaxestat, bld-0409, bld0409, bld 0409
Latest Update: 2023-04-17
Latest Update Note: News Article

Product Description

Cudetaxestat (BLD-0409) is a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis. (Sourced from: https://www.blademed.com/news/august-22-2022/)

Mechanisms of Action: Autotaxin Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Scleroderma, General *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Blade Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cudetaxestat

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B-0409-104

P1

Completed

Healthy Volunteers

2021-12-16

27%

B-0409-103

P1

Completed

Healthy Volunteers

2021-09-17

70%

B-0409-102

P1

Completed

Healthy Volunteers

2021-08-17

28%

Recent News Events